Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Malaria vaccine live attenuated - Sanaria

Drug Profile

Malaria vaccine live attenuated - Sanaria

Alternative Names: Pf delta b9 delta Slarp; PfSPZ malaria vaccine live attenuated - Sanaria; PfSPZ Vaccine - Sanaria; PfSPZ-GA1; Pf∆b9∆Slarp; Plasmodium falciparum sporozoite vaccine live attenuated - Sanaria; Sanaria PfSPZ Vaccine

Latest Information Update: 07 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; PATH; Sanaria
  • Class Attenuated vaccines; Malaria vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Falciparum malaria

Most Recent Events

  • 25 Oct 2022 Sanaria in collaboration with University of Maryland, Baltimore initiates enrolment in a phase I trial for Falciparum malaria (Prevention, In volunteers) in USA (IV) (NCT05604521)
  • 28 Jul 2022 Sanaria and Fred Hutchinson Cancer Research Center completes a phase I trial for Falciparum malaria (Prevention) in USA (IV) (NCT04966871)
  • 07 May 2022 Phase-II clinical trials in Falciparum malaria (Prevention, In adults) in Indonesia (IV) (NCT03503058)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top